SECsense Logo

Mangoceuticals, Inc. 8-K Report: Key Insights & Updates as of December 2024

$MGRX
Form 8-K
Filed on: 2024-12-19
Source
Mangoceuticals, Inc. 8-K Report: Key Insights & Updates as of December 2024

Based on the provided XML section from a financial report, here are the key insights extracted:

  1. Entity Information:
  • Name: Mangoceuticals, Inc.
  • CIK: 0001938046
  • State of Incorporation: Texas (TX)
  • SEC File Number: 001-41615
  • EIN: 87-3841292
  • Address: 15110 N. Dallas Parkway Suite 600, Dallas, TX 75248
  • Contact Number: (214) 242-9619
  1. Filing Type:
  • Form Type: 8-K (Report of unscheduled material events or corporate changes)
  • Filing Date: December 13, 2024
  1. Common Stock Details:
  • Class: Common Stock
  • Par Value: $0.0001 per share
  • Ticker Symbol: MGRX
  • Exchange: NASDAQ
  1. Context and Period:
  • Reporting Date: As of December 13, 2024
  • Period Start and End Date: December 13, 2024
  1. Units of Measure:
  • Currency: USD (United States Dollar)
  • Shares: Denoted as shares in the financial report.

Insights:

  • The report is a Form 8-K indicating a significant event or change for Mangoceuticals, Inc., which may require investor attention.
  • The company is listed on NASDAQ under the ticker MGRX, suggesting it is publicly traded and subject to SEC regulations.
  • The financial report is current as of December 13, 2024, indicating recent and potentially relevant information for stakeholders.
  • The par value of the stock is relatively low, which may be indicative of a growth-stage company or one that has undergone stock splits or restructuring.

This summary provides a concise overview of the company's essential details and the nature of the filing, which may be crucial for investors and analysts monitoring the company's performance and events.